“`html
The average one-year price target for Palvella Therapeutics (NasdaqCM:PVLA) has been raised to $133.70 per share, an increase of 15.61% from the previous estimate of $115.65 on November 14, 2025. This price target reflects a potential rise of 33.05% from the latest closing price of $100.49 per share, with estimates ranging between a low of $91.91 and a high of $210.00.
As of the last quarter, 166 institutional funds reported positions in Palvella Therapeutics, a 43.10% increase from the previous period. Total shares owned by these institutions rose by 42.68% to 8,940K shares, with an average portfolio weight of 0.14%. Additionally, the put/call ratio of 0.05 indicates a bullish outlook on the stock.
Notable shareholders include BVF with 1,161K shares (9.81% ownership), an increase of 40.02%, and Suvretta Capital Management with 822K shares (6.95% ownership), marking a 13.12% increase. Frazier Life Sciences Management maintains 722K shares (6.10% ownership), while First Light Asset Management holds 542K shares (4.58% ownership).
“`
